Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 5/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.41 |
| ▸ | GRK2 | P25098 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948370 | 0.84 | IL4I1 (0.57) | IL4I1TP53 | |
| SCHEMBL30948290 | 0.84 | IL4I1 (0.48) | IL4I1ROCK2ALDH1A1MAPK1 | |
| SCHEMBL30948193 | 0.82 | IL4I1 (0.55) | IL4I1TP53 | |
| SCHEMBL30947990 | 0.79 | IL4I1 (0.47) | IL4I1TP53 | |
| SCHEMBL30948110 | 0.79 | TP53 (0.47) | IL4I1ROCK2TP53 | |
| SCHEMBL30947904 | 0.79 | IL4I1 (0.46) | IL4I1ALDH1A1MAPK1TP53 | |
| SCHEMBL27163229 | 0.79 | IL4I1 (0.47) | IL4I1TP53 | |
| SCHEMBL30948004 | 0.77 | IL4I1 (0.47) | IL4I1TP53 | |
| SCHEMBL30947950 | 0.77 | IL4I1 (0.66) | IL4I1ROCK2SCDTP53 | |
| SCHEMBL30948084 | 0.75 | IL4I1 (0.63) | IL4I1ROCK2SCDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885ROCK2 4403/4885GRK2 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.